Sensate

Sensate owns a defensible-by-differentiation corner of the consumer calm-tech market: it is the non-electrical alternative in a category otherwise built on electrical stimulation. The palm-sized device rests on the chest and emits infrasonic vibrations below roughly 30 Hz that resonate through the sternum, synchronized with app-delivered soundscapes — an approach the company brands Somacoustics — aiming to tone the vagus nerve and strengthen the parasympathetic response to chronic stress. For the large population wary of running current through their necks (the pitch of electrical vagus stimulators like Pulsetto), a sound-and-vibration mechanism is an easier consumer sell, and the ten-minute session format fits how stressed users actually behave better than habit-heavy meditation practice. The business model is sensible for a small company: one-time hardware purchase plus a subscription content library, sold direct with a 90-day guarantee, capital-light and unburdened by medical-device regulation since it makes wellness rather than clinical claims. Company-reported pilot data — meaningfully faster sleep onset and reduced stress scores within the first month of use — gives the marketing a quantified spine, and co-founder Stefan Chmelik's clinical background in integrative medicine anchors the scientific narrative. The stress, anxiety, and sleep market is enormous, chronic, and poorly served by pharmaceuticals; a £2.7M seed led by Incisive Ventures in 2023 bought entry into it at a fraction of what neurostimulation rivals have raised, meaning even niche-scale traction produces venture-relevant returns on the capital actually deployed.